Key Dates

NOT-NS-21-033 - Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)

National Institute of Neurological Disorders and Stroke (NINDS)

National Eye Institute (NEI)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Mental Health (NIMH)

National Center for Complementary and Integrative Health (NCCIH)

The National Institute for Neurological Disorders and Stroke, along with other NIH Institutes and Centers (ICs), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in March, 2021 with an expected application due date in April, 2021.

This FOA will utilize the R34 activity code. Details of the planned FOA are provided below.

Through targeted research efforts, the NIH HEAL Initiative, proposes to accelerate the discovery and preclinical development of new medications to treat pain. This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe and effective therapeutics to treat pain with little or no addiction liability.

The goal of this funding opportunity announcement (FOA) will be to solicit Initial Analgesic Development (R34) applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease

Webinar

In order to learn more about this FOA and to have the opportunity to ask questions, a pre-application informational webinar will be held on Thursday, March 11, 2021 from 3:00-4:00 pm EDT (12:00-1:00pm PDT). This webinar will also be recorded and disseminated to the general public. Information on how to join the webinar is provided below:

RFA Webinar: "HEAL Initiative: Translational Efforts in Non-addictive Analgesic Development"

To join the web presentation, at least 10 minutes before the starting time:

1. Go to https://nih.zoomgov.com/j/1601307575?pwd=R2ZjK2lKNUJJVlQ4ek1BamtrRE5ZUT09

2. Click "Join Now"

For audio you can follow the prompts on your monitor, or:

Call-in toll number (US):

+1 669 254 5252 US (San Jose)
+1 646 828 7666 US (New York)
+1 669 216 1590 US (San Jose)
+1 551 285 1373 US

Find your local number: https://nih.zoomgov.com/u/adqgk3nzZN

Meeting ID: 160 130 7575
Passcode: 574104

For assistance please contact Alex Tuttle, Ph.D. [E] alex.tuttle@nih.gov

Applications are not being solicited at this time.

Please direct all inquiries to:

Michael Oshinsky

National Institute of Neurological Disorders and Stroke (NINDS)

301-496-9964

michael.oshinsky@nih.gov

D.P. Mohapatra, PhD

National Institute of Neurological Disorders and Stroke (NINDS)

Telephone: 301-496-9964

Email: dp.mohapatra@nih.gov

Rebecca Roof, PhD

National Institute of Neurological Disorders and Stroke (NINDS)

Telephone: 301-496-1779

Email: Rebecca.Roof@nih.gov